Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-004

Irvine, CA – February 18, 2021 – Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-004 to treat vascularized pinguecula. The Phase 2 […]

Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006

Irvine, CA – November 30, 2020 – Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-006 to treat Meibomian Gland Dysfunction Associated Dry […]